Supreme Court advocate Jaikush Hoon highlighted safety concerns over GLP-1 drugs, including Ozempic (semaglutide), Mounjaro (tirzepatide), and Victoza (liraglutide). "It has been observed that doctors are prescribing these drugs alongside Ozempic. These medicines, which have been associated with serious potential adverse consequences in the United States and globally, ought to be subject to strict regulation and limited exceptions in India as well," Hoon said. He warned that reports of such drugs being available over the counter without prescriptions were a "matter of grave concern," contravening the Drugs and Cosmetics Act, 1940, and posing significant public health risks in the absence of medical supervision.